Shots:

• Mundipharma to get exclusive commercialization rights for Samsung Bioepis’ first-wave biosimilar candidates in Taiwan and Hong Kong while Samsung Bioepis will remain MAH- responsible for the development- regulatory and manufacturing activities of therapies
• The biosimilar candidates include SB5 (adalimumab)- SB4 (etanercept)- SB3 (trastuzumab)- and SB8 (bevacizumab) targeting immunology & oncology
• The collaboration combines Samsung Bioepis' biosimilar development platform with Mundipharma's commercial acumen and market insight to address the medical needs of patients in the licensed territories

Click here ­to­ read full press release/ article 

 Ref: PRNewswire  | Image: Samsung Bioepis